Search

Researchers from The Kids Research Institute Australia have identified the main bacteria responsible for recurrent ear infections and repeat ear surgeries in children.

The year 2020 has been marked by possibly the greatest health challenge to face modern society. The emergence of COVID-19 as a novel human pathogen

The Kids Research Institute Australia researchers will lead a new national clinical trial (COSI-2) to determine whether topical coconut oil can reduce late onset sepsis in extremely preterm infants.

Seven important The Kids Research Institute Australia research projects have received support from the Future Health Research and Innovation Fund through the WA Near-Miss Awards (WANMA).

Paediatric audiologist Associate Professor Chris Brennan-Jones has been announced as a finalist for the country’s leading national science awards – the Australian Museum Eureka Prizes.

World-first immunisations providing protection against deadly respiratory syncytial virus (RSV) could be just months away thanks to global research efforts spanning multiple decades.

Researchers from The Kids Research Institute Australia are joining forces with international experts in acute rheumatic fever (ARF) and rheumatic heart disease (RHD) to transform the diagnosis of these diseases thanks to an $US8 million grant from the Leducq Foundation.

Young Aboriginal and Torres Strait Islander people receiving long-term, painful injections to prevent deadly complications from rheumatic heart disease (RHD) will design their own optimum treatment program thanks to latest research at The Kids Research Institute Australia.

Researchers from The Kids Research Institute Australia have been awarded more than $11 million to support vital child health projects, under the Federal Government’s Medical Research Future Fund.

Invasive fungal disease (IFD) remains a challenging complication of treatment for paediatric acute leukaemia. Consensus fungal treatment guidelines recommend withholding chemotherapy to facilitate immune recovery in this setting, yet prolonged delays in leukaemia therapy increase risk of relapse.